CM
GPCR icon

Crestline Management’s Structure Therapeutics GPCR Stock Holding History

Crestline Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,310
Closed -$233K – 790
2024
Q3 		$233K Buy
+5,310
New +$205K 0.01% 487

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Crestline Management's GPCR Position: Q4 2024 in Review

Crestline Management sold out of Structure Therapeutics (GPCR) in Q4 2024, closing a stake of 5,310 shares — an estimated $233K sold.

Crestline Management first reported a position in GPCR in Q3 2024 and held it in 1 quarter. The position peaked at $233K in Q3 2024. 164 funds tracked by Wall St. Rank hold GPCR as of Q4 2024.

  • Crestline Management reported no remaining Structure Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Crestline Management sold 5,310 Structure Therapeutics shares in Q4 2024, an estimated $233K.
  • Crestline Management first reported a position in Structure Therapeutics in Q3 2024 and held it in 1 quarter.
  • Crestline Management's Structure Therapeutics position peaked at $233K in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2024.

Based on Crestline Management's 13F filing for Q4 2024, filed 14 Feb 2025.